ObjectivePatients with renal failure suffer from symptoms caused by uraemic toxins, possibly of gut microbial origin, as deduced from studies in animals. The aim of the study is to characterise relationships between the intestinal microbiome composition, uraemic toxins and renal failure symptoms in human end-stage renal disease (ESRD).DesignCharacterisation of gut microbiome, serum and faecal metabolome and human phenotypes in a cohort of 223 patients with ESRD and 69 healthy controls. Multidimensional data integration to reveal links between these datasets and the use of chronic kidney disease (CKD) rodent models to test the effects of intestinal microbiome on toxin accumulation and disease severity.ResultsA group of microbial species enriched in ESRD correlates tightly to patient clinical variables and encode functions involved in toxin and secondary bile acids synthesis; the relative abundance of the microbial functions correlates with the serum or faecal concentrations of these metabolites. Microbiota from patients transplanted to renal injured germ-free mice or antibiotic-treated rats induce higher production of serum uraemic toxins and aggravated renal fibrosis and oxidative stress more than microbiota from controls. Two of the species, Eggerthella lenta and Fusobacterium nucleatum, increase uraemic toxins production and promote renal disease development in a CKD rat model. A probiotic Bifidobacterium animalis decreases abundance of these species, reduces levels of toxins and the severity of the disease in rats.ConclusionAberrant gut microbiota in patients with ESRD sculpts a detrimental metabolome aggravating clinical outcomes, suggesting that the gut microbiota will be a promising target for diminishing uraemic toxicity in those patients.Trial registration numberThis study was registered at ClinicalTrials.gov (NCT03010696).

The successful recognition of pathogen-associated molecular patterns (PAMPs) as a danger signal is crucial for plants to fend off numerous potential pathogenic microbes. The signal is relayed through mitogen-activated protein kinase (MPK) cascades to activate defenses. Here, we show that the Pseudomonas syringae type III effector HopF2 can interact with Arabidopsis thaliana MAP KINASE KINASE5 (MKK5) and likely other MKKs to inhibit MPKs and PAMP-triggered immunity. Inhibition of PAMP-induced MPK phosphorylation was observed when HopF2 was delivered naturally by the bacterial type III secretion system. In addition, HopF2 Arg-71 and Asp-175 residues that are required for the interaction with MKK5 are also necessary for blocking MAP kinase activation, PAMP-triggered defenses, and virulence function in plants. HopF2 can inactivate MKK5 and ADP-ribosylate the C terminus of MKK5 in vitro. Arg-313 of MKK5 is required for ADP-ribosylation by HopF2 and MKK5 function in the plant cell. Together, these results indicate that MKKs are important targets of HopF2.

Complex interfaces stabilized by proteins, polymers or nanoparticles, have a much richer dynamics than those stabilized by simple surfactants. By subjecting fluid-fluid interfaces to step extension-compression deformations, we show that in general these complex interfaces have dynamic heterogeneity in their relaxation response that is well described by a Kohlrausch-Williams-Watts function, with stretch exponent β between 0.4–0.6 for extension, and 0.6–1.0 for compression. The difference in β between expansion and compression points to an asymmetry in the dynamics. Using atomic force microscopy and simulations we prove that the dynamic heterogeneity is intimately related to interfacial structural heterogeneity and show that the dominant mode for stretched exponential relaxation is momentum transfer between bulk and interface, a mechanism which has so far largely been ignored in experimental surface rheology. We describe how its rate constant can be determined using molecular dynamics simulations. These interfaces clearly behave like disordered viscoelastic solids and need to be described substantially different from the 2d homogeneous viscoelastic fluids typically formed by simple surfactants.

Combination therapy with enhanced therapeutic and antimetastatic efficacy has become promising for cancer treatment. There is an urgent need to design a co-delivery system to sequentially release the drug pair at desired locations that can increase the intra-tumoral drug concentration and reduce the side effects. Inspired by virus architecture and function, herein, we developed a peptosome (PS)-based co-delivery system, PePm/PS/Curcumin (Cur), for the sequential release of the therapeutic peptide Pe and chemodrug Cur. PS was formed by the self-assembly of amphiphilic α-lactalbumin peptides obtained from enzymatic partial hydrolysis. Then, PS was self-cross-linked with disulfide bonds utilizing their endogenous thiol groups. The system is responsive to multiple tumor microenvironments and releases the drugs at specific tumor locations. First, after PS accumulation in tumor tissue via the EPR effect, the linkage peptide Pm in PS can be cleaved by matrix metalloproteinases (MMP) enzymatic hydrolysis. Pe can stay on the cell surface and antagonize the ErbB-2 receptor expression on the tumor cells. Moreover, the positively charged nature of remaining Mal-PS/Cur facilitates tumor cell internalization and induces a subsequent proton-sponge effect for lysosomal escape. Finally, Cur is released in the cytoplasm via a reduction-induced PS disassembly due to the high level of intracellular GSH. Both the in vitro and in vivo results exhibited an enhanced antitumor and antimetastatic efficacy of this system.

The codelivery system for multiple antioxidants such as anthocyanins (Ant) and curcumin (Cur) of synergistic action may effectively enhance their stability and cellular absorption. We have reported that amphiphilic peptides obtained from enzymatic partial hydrolysis of α-lactalbumin (α-lac) can self-assemble into 20 nm monodispersed nanomicelles in aqueous solution. Cur and Ant could be coloaded into the micelles sequentially via hydrophobic and electrostatic interactions, which was proved by fluorescence quenching experiments for the Cur–micelle and Ant–micelle interactions. Circular dichroism spectra proved that the Cur and Ant binding did not affect their structure confirmation. Both Cur- and Ant-loaded micelles showed improved stability and also exhibited an intestinal pH responsive release property in simulated gastrointestinal fluid. In addition, the nanomicelles exhibited an advanced cellular uptake and transmembrane permeability based on Caco-2 cell monolayer models. Finally, the coloaded micelles possessed a synergistic efficiency such that cellular antioxidant activity (CAA) for Cur and Ant was markedly improved.